
Roche has published healthy revenue growth for the first half of 2012, but its profits have taken a hit. The …

Roche has abandoned its Phase III cholesterol treatment dalcetrapib after disappointing results.The manufacturer is ceasing work on the drug, once …
Boyds expands Regulatory Affairs team to support growing demand
Sterling doubles ADC manufacturing capacity at Welsh facility
Femtosecond laser cuts lung tumour margin assessment time
Blood sensor detects Parkinson’s-associated proteins in 40 minutes

